Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine

Memory Mvula,Fatima Mtonga,Jonathan Mandolo,Chisomo Jowati,Alice Kalirani,Precious Chigamba,Edwin Lisimba,Ndaona Mitole,Marah G. Chibwana,Kondwani C. Jambo
DOI: https://doi.org/10.1186/s12879-024-09891-z
IF: 3.7
2024-09-13
BMC Infectious Diseases
Abstract:Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines.
infectious diseases
What problem does this paper attempt to address?